Circular Genomics Secures $15 Million Series A for Alzheimer's Blood Test

Circular Genomics has closed a $15 million Series A financing round dedicated to advancing its proprietary circular RNA (circRNA) platform for the early detection of Alzheimer's disease (AD).

The funding round was led by Mountain Group Partners, with participation from Poplar Grove Investors, HIP Fund, and the Alzheimer's Drug Discovery Foundation (ADDF).

This influx of capital will directly fuel the clinical validation and commercial preparation of the diagnostic technology, positioning the company to transition its platform from research validation into clinical deployment. The company asserts that circRNAs represent a superior class of brain-derived blood biomarkers capable of identifying AD pathology earlier than current methods allow. The urgency for this technology is amplified by recent regulatory approvals for disease-modifying AD therapies, which necessitate accurate, accessible tools to identify patients in preclinical or very early symptomatic stages.

Traditional diagnostic avenues, such as PET scans and cerebrospinal fluid taps, remain expensive, invasive, and geographically restrictive for broad patient screening. Proceeds from the Series A will be strategically allocated across multiple fronts, including expanding validation studies across diverse patient cohorts to establish platform robustness.

Furthermore, the company intends to enhance the biomarker platform to encompass other neurodegenerative and psychiatric conditions beyond the initial Alzheimer's focus. Circular Genomics is also prioritizing the establishment of strategic partnerships with pharmaceutical developers and diagnostic service providers to expedite market penetration. This strategic expansion includes recruiting specialized talent across regulatory affairs, commercial operations, and advanced clinical development teams. The competitive landscape in accessible AD diagnostics is heating up considerably, especially following the recent funding secured by competitors focused on plasma-based protein assays.

Circular Genomics differentiates itself by leveraging the stability and brain-enrichment of circRNAs, which offer insights into multiple disrupted biological pathways central to AD progression.

Company leadership indicated that the data supporting the platform’s performance will be presented shortly at the Clinical Trials on Alzheimer's Disease (CTAD) Conference. These forthcoming findings are expected to detail the platform’s predictive modeling capabilities against established benchmarks like CSF analysis and Amyloid PET positivity. Ultimately, success in this domain could fundamentally alter the standard of care for neurological disorders by enabling proactive intervention before irreversible cognitive decline occurs.

This shift from late-stage reactive assessment to early-stage precision biology represents the core value proposition underpinning this latest investment.